Investor Presentaiton
Summary
Global leader in Targeted Copper Theranostics (TCT)
Extensive pipeline of TCTs based on 64Cu for diagnosis and 67Cu for therapy
■ TCTs address the current manufacturing and logistical limitations in the growth of
radiopharmaceuticals
■ TCT are scalable, sustainable and dependable
Broad and defensible IP portfolio of patent families across the SAR Technology
platform, pipeline and products
Pipeline includes large and orphan indications, with focus on the US for first
approvals
Well funded with $95.9M in cash
Led by an experienced management team and Board with significant years of
active involvement in the radiopharmaceutical industry
Hot sector of the market with numerous recent acquisitions.
CLARITY
2014 MEIE
64CU SAR-bisPSMA
PET/CT in mCRPC
34View entire presentation